The FDA has granted orphan drug designation to Cambium Medical Technologies’ fibrinogen-depleted human platelet lysate for the treatment of ocular graft-versus-host disease, according to a press release.
Elate Ocular is currently in phase 1/2 trials for the treatment of dry eye secondary to ocular graft-versus-host disease. The designation will provide benefits and incentives for development and commercialization for Elate as a promising treatment for a rare disease.
“We are honored to be awarded orphan drug status. It is another key milestone in the development of our Elate Ocular
Uncategorized